We report a case of secondary osteoporosis treated with a combination of vitamins D 3 and K 2 , administered orally. A 13-year-old male, diagnosed with highly differentiated acute myelogenous leukaemia, received an allogeneic bone-marrow transplantation. Chronic graft-versus-host disease persisted, thereafter, in the form of severe diarrhoea, rash and allergic conjunctivitis. Since the patient was then at risk from osteoporosis secondary to calcium malabsorption caused by the diarrhoea, dual-energy X-ray absorptiometry and ultrasound analysis were used to measure bone mineral density and bone stiffness, respectively. Both measurements were markedly lower than the average values from patients of matched age, gender and physical characteristics. The osteoporosis did not respond to active vitamin D 3 0.1 µg/kg once daily, but when this therapy was combined with vitamin K 2 15 mg once daily, an increase in bone mineral density and bone stiffness was observed. In conclusion, vitamin D 3 and K 2 combination therapy merits further evaluation for the treatment of various types of secondary osteoporosis, including steroid-induced osteoporosis.
Introduction
Proteins containing γ-carboxyglutamic acid (Gla protein), including the non-collagenous calcium-binding protein, osteocalcin, are abundant in the bone matrix. Carboxylated osteocalcin has an affinity for calcium ions and plays an important role in bone calcification. Since γ-carboxylation of osteocalcin is dependent on vitamin K, this vitamin is thought to have a beneficial effect on bone calcium turnover by modulating the process. 1 -3 Among the vitamin K derivatives, vitamin K 2 may not only promote osteogenesis but may also suppress bone resorption. 4 This has encouraged its use in the treatment of osteoporosis, and osteoporotic patients have been reported to respond to this therapy. 5 This report describes a 13-year-old male with highly differentiated acute myelogenous leukaemia (AML) who had undergone allogeneic bone-marrow transplantation, for which his sibling was M Hattori, N Morita, Y Tsujino et al.
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the donor. Following transplantation, the patient developed osteoporosis secondary to severe diarrhoea that was brought about by graft-versus-host disease (GVHD). We report the successful treatment of this patient with vitamin D 3 and K 2 combination therapy.
Case report
A 12-year-old male patient consulted a local physician because of facial pallor and fever in October 1996. He was immediately admitted to a municipal hospital due to persistent fever. Haematological tests showed severe leucocytosis (white blood cell count, 57 400/µl; red blood cell count, 2 160 000/µl; haemoglobin level, 7.4 g/dl; and platelet count, 22 000/µl). This suggested a diagnosis of leukaemia, and the patient was transferred to Hyogo College Hospital, Japan. Further haematological tests carried out on admission showed a white blood cell count of 51 100/µl (61% blast cells); red blood cells, 2 110 000/µl; haemoglobin, 5.9 g/dl; and platelet count, 25 000/µl. Bone-marrow aspiration performed 3 days later showed a nucleated cell count of 219 000/µl, > 90% of which were myeloblasts, and a megakaryocyte count of 15.6/µl. A diagnosis of highly differentiated AML (M3 according to the French-American-British Cooperative Group criteria) was made based on these findings.
On 17 October, the patient received chemotherapy according to the AML protocol. On 19 November, a bone-marrow examination showed complete remission. In light of the generally poor prognosis of AML, the patient underwent allogeneic bonemarrow transplantation from a genotypically human-leucocyte antigen-identical sibling (younger sister) donor on 28 February 1997. On 9 June (post-transplant day 101), the patient developed Grade III GVHD with symptoms of diarrhoea, conjunctivitis and hepatic dysfunction. On post-transplant day 112, the GVHD worsened to Grade IV with abdominal pain. A plain X-ray of the patient's abdomen showed signs of paralytic ileus. Treatment with cyclosporin, methylprednisolone and tacrolimus improved the ileus; however, chronic GVHD persisted in the form of diarrhoea (watery stools three to five times per day), rash and allergic conjunctivitis.
Since the persistent severe diarrhoea might have resulted in osteoporosis secondary to calcium malabsorption, the patient's bone mineral density was measured on 14 October 1997. Dual energy X-ray absorptiometry (model XR26, Norland Corp., Fort Atkinson, WI, USA) was used to determine the mean bone mineral density in the second to fourth lumbar vertebrae (L2 -4). To avoid excessive exposure to radiation, assessment of bone mass was subsequently replaced by measurement of bone stiffness (%) at the calcaneus, using an Achilles ultrasonometer (Lunar Corp., Madison, WI, USA). This has been shown to correlate with bone mineral density (bone mass) as measured by dual energy X-ray absorptiometry. 6 The changes in bone stiffness in response to therapy are shown in Fig. 1 . On 14 October, the L2 -4 mean bone mineral density and bone stiffness were 0.629 g/cm 2 and 46%, respectively. These values are markedly lower than the respective normal values from patients of matched age, gender and physical characteristics (i.e. bone mineral density of 0.680 g/cm 2 and bone stiffness of 82%). Since fracture (lumbar compression fracture in particular) was a risk, the patient was advised to abstain from strenuous physical activity and was treated with a once-daily oral dose of 0.1 µg/kg active vitamin D 3 (alphacalcidol).
On 22 January 1998, after 3 months of treatment with alphacalcidol, the serum osteocalcin level increased to 22.2 ng/ml (normal range is 3.1 -12.7 ng/ml). The bone mineral density and bone stiffness remained low at 0.615 g/cm 2 and 49%, respectively. Since fracture was still a risk, despite the patient avoiding strenuous physical activity, vitamin D 3 therapy was combined with a once-daily dose of 15 mg vitamin K 2 (menatetrenone), administered orally after the evening meal. A 55% increase in bone stiffness was observed 3 months after the addition of vitamin K 2 . Bone stiffness increased steadily to 62% in the subsequent 3 months (21 July 1998), to 66% on 11 January 1999 and to 73% on 9 November 2000. The serum osteocalcin level showed a further increase to 31.1 ng/ml. During the therapy, the blood concentration of vitamin K 2 was increased by 5.26 ng/ml compared with the normal range (i.e. < 0.10 ng/ml). The patient developed no adverse reactions to vitamin D 3 or K 2 , such as hypercalcaemia or abdominal discomfort.
As of 22 December 2000, the patient still had loose bowels (bowel movements once or twice a day) but was free of the primary malignancy and enjoying a normal school life without any restrictions on his daily activities.
Discussion
Osteoporosis primarily affects adults and rarely occurs in children because primary osteoporosis, including post-menopausal and senile osteoporosis, is the predominant type. Secondary osteoporosis may occur in association with various endocrine, gastrointestinal and haematological diseases. 7 The patient reported herein developed osteoporosis secondary to calcium malabsorption caused by gastrointestinal symptoms of GVHD (e.g. diarrhoea) following allogeneic bone-marrow transplantation. To improve the efficiency of gastrointestinal absorption of calcium, M Hattori, N Morita, Y Tsujino et al. active vitamin D 3 (alphacalcidol) monotherapy was administered for 3 months. Among the various methods of assessing bone mass, 8 dual energy X-ray absorptiometry was used to determine the bone mineral density in the L2 -4 vertebrae. The bone mass was also assessed by measuring bone stiffness, which has been shown to correlate with bone mineral density measured by dualenergy X-ray absorptiometry. 6 Since vitamin D 3 monotherapy did not improve bone mineral density or stiffness, vitamin K 2 was used in combination with vitamin D 3 to facilitate vitamin K-dependent γ-carboxylation of osteocalcin. Vitamin D 3 and K 2 combination therapy increased the bone mineral density, probably by a synergistic mechanism whereby vitamin D 3 induced osteocalcin, the γ-carboxylation of which may subsequently have been promoted by vitamin K 2 , thereby accelerating bone mineralization. This supposition is supported by the finding of Koshihara et al. 9 ,10 that carboxylated osteocalcin accumulates in the extracellular matrix of the osteoblast cell layer after the administration of vitamin K 2 .
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Vitamin D 3 and K 2 combination therapy merits further evaluation for the treatment of various types of secondary osteoporosis, including steroid-induced osteoporosis. Although vitamin K 2 is contraindicated in patients receiving warfarin, vitamin D 3 and K 2 combination therapy may also be effective for primary osteoporosis.
